Churchill Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Churchill Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-58,056	Closed	-$10.7M	–	164
2021 Q2	$10.7M	Buy	58,056 +13,130	+29%	+$2.25M	0.16%	85
2021 Q1	$6.87M	Buy	44,926 +1,600	+4%	+$248K	0.11%	108
2020 Q4	$6.77M	Buy	43,326 +3,124	+8%	+$401K	0.12%	107
2020 Q3	$4.6M	Buy	40,202 +5,167	+15%	+$557K	0.11%	92
2020 Q2	$3.93M	Buy	+35,035	New	+$3.72M	0.12%	83
2014 Q2	–	Sell	-319,402	Closed	-$48.6M	–	214
2014 Q1	$48.6M	Sell	319,402 -9,253	-3%	-$1.47M	1.91%	16
2013 Q4	$43.7M	Buy	+328,655	New	+$39.4M	1.67%	17

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Churchill Management's ALXN Position: Q3 2021 in Review

Churchill Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 58,056 shares — an estimated $10.7M sold.

Churchill Management first reported a position in ALXN in Q4 2013 and held it in 7 quarters. The position peaked at $48.6M in Q1 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Churchill Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Churchill Management sold 58,056 Alexion Pharmaceuticals shares in Q3 2021, an estimated $10.7M.
Churchill Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 7 quarters.
Churchill Management's Alexion Pharmaceuticals position peaked at $48.6M in Q1 2014.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Churchill Management's 13F filing for Q3 2021, filed 13 Oct 2021.